These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 1854589

  • 1. Augmentation of antitumor effect on syngeneic murine solid tumors by an interleukin 2 slow delivery system, the IL-2 mini-pellet.
    Fujiwara T, Sakagami K, Matsuoka J, Shiozaki S, Fujioka K, Takada Y, Uchida S, Onoda T, Orita K.
    Biotherapy; 1991; 3(3):203-9. PubMed ID: 1854589
    [Abstract] [Full Text] [Related]

  • 2. Antitumor effects of a new interleukin-2 slow delivery system on methylcholanthrene-induced fibrosarcoma in mice.
    Fujiwara T, Sakagami K, Orita K.
    J Cancer Res Clin Oncol; 1990; 116(2):141-8. PubMed ID: 2324156
    [Abstract] [Full Text] [Related]

  • 3. Enhanced activity against syngeneic murine tumors by intrasplenic injection of recombinant interleukin-2 (IL-2) and interleukin-1 (IL-1).
    Nakajima I, Ozaki M, Jinnai H, Shilayama Y, Hirohata T, Okuno K, Yasutomi M.
    Cancer Biother; 1993; 8(4):319-26. PubMed ID: 7804373
    [Abstract] [Full Text] [Related]

  • 4. [The anti-tumor efficacy of human recombinant interleukin-2 (rIL-2) in vivo].
    Wang C, Chai L, Zhu G.
    Zhonghua Zhong Liu Za Zhi; 1995 Jan; 17(1):27-9. PubMed ID: 7656782
    [Abstract] [Full Text] [Related]

  • 5. Effect of Krestin (PSK) on the induction of IL-2 activated killer cells.
    Sakamaki S, Kohgo Y, Nojiri S, Kanisawa Y, Ito Y, Takahashi M, Ueno Y, Hirayama Y, Niitsu Y.
    Jpn J Clin Oncol; 1992 Apr; 22(2):79-83. PubMed ID: 1619782
    [Abstract] [Full Text] [Related]

  • 6. Interleukin-2 and syngeneic bone marrow transplantation in a murine fibrosarcoma model.
    Ho SP, Stebler B, Ershler WB.
    Lymphokine Cytokine Res; 1991 Apr; 10(1-2):101-4. PubMed ID: 1873353
    [Abstract] [Full Text] [Related]

  • 7. Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model.
    Marincola FM, Da Pozzo LF, Drucker BJ, Holder WD.
    Surgery; 1990 Nov; 108(5):919-29. PubMed ID: 2237773
    [Abstract] [Full Text] [Related]

  • 8. Augmentation of anti-tumor effect of interleukin 2 with sizofiran in mice.
    Ikeuchi K.
    Keio J Med; 1991 Sep; 40(3):132-8. PubMed ID: 1753556
    [Abstract] [Full Text] [Related]

  • 9. Anti-tumor effects of interleukin-2 and interleukin-1 in mice transplanted with different syngeneic tumors.
    Belardelli F, Ciolli V, Testa U, Montesoro E, Bulgarini D, Proietti E, Borghi P, Sestili P, Locardi C, Peschle C.
    Int J Cancer; 1989 Dec 15; 44(6):1108-16. PubMed ID: 2606579
    [Abstract] [Full Text] [Related]

  • 10. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells.
    Saarloos MN, Khoo NK, Lala PK.
    Cancer Res; 1992 Dec 01; 52(23):6452-62. PubMed ID: 1423293
    [Abstract] [Full Text] [Related]

  • 11. Use of N-acetyl cysteine to increase intracellular glutathione during the induction of antitumor responses by IL-2.
    Yim CY, Hibbs JB, McGregor JR, Galinsky RE, Samlowski WE.
    J Immunol; 1994 Jun 15; 152(12):5796-805. PubMed ID: 8207209
    [Abstract] [Full Text] [Related]

  • 12. Antitumor effect of interleukin-1 beta in the double grafted tumor system.
    Ebina T, Ishikawa K.
    Jpn J Cancer Res; 1989 Jun 15; 80(6):570-6. PubMed ID: 2503477
    [Abstract] [Full Text] [Related]

  • 13. Immunotherapy by a slow delivery system of interleukin-2 in mice models.
    Matsuoka J, Sakagami K, Fujiwara T, Onoda T, Idani H, Gochi A, Orita K.
    Acta Med Okayama; 1993 Apr 15; 47(2):79-84. PubMed ID: 8506753
    [Abstract] [Full Text] [Related]

  • 14. Immunotherapy with low-dose interleukin-2 and a polysaccharopeptide derived from Coriolus versicolor.
    Mao XW, Archambeau JO, Gridley DS.
    Cancer Biother Radiopharm; 1996 Dec 15; 11(6):393-403. PubMed ID: 10851500
    [Abstract] [Full Text] [Related]

  • 15. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I, Komuta K, Hara H, Inoue T, Hosoe S, Ikeda T, Shirasaka T, Yokota S, Tanio Y, Masuno T.
    Cancer Res; 1988 Mar 01; 48(5):1173-9. PubMed ID: 3257715
    [Abstract] [Full Text] [Related]

  • 16. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
    Maekawa R, Kitagawa T, Koizumi K, Sato K, Homma M.
    J Biol Response Mod; 1989 Dec 01; 8(6):676-90. PubMed ID: 2600605
    [Abstract] [Full Text] [Related]

  • 17. Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice.
    Hirahara N, Nio Y, Sasaki S, Minari Y, Takamura M, Iguchi C, Dong M, Yamasawa K, Tamura K.
    Oncology; 2001 Dec 01; 61(1):79-89. PubMed ID: 11474253
    [Abstract] [Full Text] [Related]

  • 18. Immunotherapy with low-dose interleukin-2 and anti-transforming growth factor-beta antibody in a murine tumor model.
    Mao XW, Kettering JD, Gridley DS.
    Cancer Biother; 1994 Dec 01; 9(4):317-27. PubMed ID: 7719379
    [Abstract] [Full Text] [Related]

  • 19. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
    Wakizaka Y.
    Hokkaido Igaku Zasshi; 1992 Jul 01; 67(4):475-87. PubMed ID: 1330859
    [Abstract] [Full Text] [Related]

  • 20. Augmentation of murine lymphokine-activated killer cell cytotoxicity by beta-cyclodextrin-benzaldehyde.
    Kuroki Y, Ochiai H, Kurokawa M, Niwayama S, Kishimoto C, Tazawa K, Fujimaki M.
    J Cancer Res Clin Oncol; 1991 Jul 01; 117(2):109-14. PubMed ID: 2007609
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.